Study urges industry to be more transparent and fairer in selecting speakers, and to recruit more women to steering ...

The First Trust Morningstar Dividend Leaders ETF (FDL) was launched on 03/09/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Value segment of ...

With numerous commitments made in VPAG, time will tell how transparent the government ... leavers of the predecessor scheme VPAS – AbbVie and Eli Lilly – there will be interest in whether ...

Total Access Medical (TAM) is excited to announce that FJ Leto has been appointed as the new President of the organization. Mr. Leto is poised to lead TAM into a transformative phase of redefining ...

Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the Vanguard Health Care ETF (VHT), a passively managed exchange traded fund launched on ...

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund launched on 12/20/2011.

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...

AbbVie (NYSE:ABBV) will report Q4 2024 results next week and provide guidance for 2025. The company is handling the erosion of Humira quite well, but the trajectory of the decline in Humira's net ...

Well before the market open, news broke of those two AbbVie price target increases. They came at the kickoff of the week, when the company was scheduled to post its fourth-quarter earnings (on ...